Tag: leukemia

Evidence Rating Level: 2 (Good)  1. Combination therapy of Ibrutinib and Venetoclax may be successful first-line treatments for patients with Chronic Lymphocytic Leukemia (CLL) who are currently not undergoing treatment  2. This combination therapy had a 3-year progression free survival (PFS) of 93% in first line treatment of CLL  The evolution and...
1. Bruton’s tyrosine kinase inhibitor pirtobrutinib showed efficacy in the treatment of relapsed or refractory B-cell malignancies such as chronic lymphocytic leukemia, mantle cell lymphoma, Waldenstrom macroglobulinemia and marginal zone lymphoma. 2. Pirtobrutinib had a manageable safety profile, with few grade 3 or more adverse events. Evidence Rating Level: 1 (Excellent) Study...
1. Patients with hematological malignancies were found to be at an increased risk of COVID-19 and were more likely to require admission to the intensive care unit for ventilation. 2. Among adult cancer patients with confirmed SARS-CoV-2 infection, the case-fatality rate was higher in male patients compared to female patients.  Evidence...